Adjuvant Discovery for Vaccines against West Nile Virus and Influenza

佐剂发现计划支持新型疫苗佐剂候选物的早期发现和初步表征。研究必须包括（1）通过高通量筛选（HTS）方法鉴定新型佐剂候选物，并验证先导化合物刺激人体细胞； (2) 确定选定的先导化合物的作用机制，包括鉴定候选佐剂所作用的受体以及它们激活的细胞信号传导途径； (3) 以构效关系（SAR）研究为指导，通过配方和药物化学优化先导佐剂候选物； (4)在动物模型中验证先导化合物作为体内疫苗佐剂的功效。 项目必须包括动物模型研究，以测试候选佐剂与疫苗： A) 一种或多种 NIAID 新出现和重新出现的传染病病原体 http://www.niaid.nih.gov/topics/emerging/pages/default.aspx)，或 B)一种或多种NIAID新出现和再出现的传染病病原体以及一种或多种与人类疾病相关的其他（非HIV）病原体。

The Adjuvant Discovery Program supports the early stage discovery and initial characterization of novel adjuvant candidates for vaccines. The research must include (1) identification of novel adjuvant candidates through high throughput screening (HTS) approaches and validation that lead compounds stimulate human cells; (2) determination of the mechanism of action of select lead compounds, including the identification of the receptor(s) the adjuvant candidates work through and the cellular signaling pathways they activate; (3) optimization of lead adjuvant candidates through formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies; and (4) verification of the efficacy of lead compounds as vaccine adjuvants in vivo in an animal model. Projects must include animal model studies to test the adjuvant candidates with vaccines against: A) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens http://www.niaid.nih.gov/topics/emerging/pages/default.aspx), or B) One or more NIAID Emerging and Re-emerging Infectious Disease Pathogens as well as one or more other (non-HIV) pathogens relevant to human disease.